LP
ACRS icon

LMR Partners’s Aclaris Therapeutics ACRS Stock Holding History

LMR Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-48,360
Closed -$74K – 1356
2025
Q1 		$74K Buy
+48,360
New +$103K ﹤0.01% 1171
2021
Q2 		– Sell
-26,974
Closed -$680K – 1092
2021
Q1 		$680K Buy
+26,974
New +$528K 0.02% 563
2020
Q4 		– Sell
-11,420
Closed -$29K – 482
2020
Q3 		$29K Sell
11,420
-2,015
-15% -$4.51K ﹤0.01% 408
2020
Q2 		$22K Buy
+13,435
New +$18K ﹤0.01% 567

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

LMR Partners's ACRS Position: Q2 2025 in Review

LMR Partners sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 48,360 shares — an estimated $74K sold.

LMR Partners first reported a position in ACRS in Q2 2020 and held it in 4 quarters. The position peaked at $680K in Q1 2021. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • LMR Partners reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • LMR Partners sold 48,360 Aclaris Therapeutics shares in Q2 2025, an estimated $74K.
  • LMR Partners first reported a position in Aclaris Therapeutics in Q2 2020 and held it in 4 quarters.
  • LMR Partners's Aclaris Therapeutics position peaked at $680K in Q1 2021.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on LMR Partners's 13F filing for Q2 2025, filed 14 Aug 2025.